EVO 101
Alternative Names: EVO-101Latest Information Update: 04 Oct 2023
At a glance
- Originator Evommune
- Class Anti-inflammatories; Skin disorder therapies; Small molecules
- Mechanism of Action IRAK4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Atopic dermatitis; Rosacea